Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor (EGFR) Mutations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07548060
What this trial is testing

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

Who this might be right for
NSCLC Stage IVEGFR Gene Mutation
Tianjin Medical University Cancer Institute and Hospital 25
Not applicableStudy completedNCT00883480
What this trial is testing

Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma

Who this might be right for
Non-small Cell Lung Cancer
Spanish Lung Cancer Group 153
Large-scale testing (Phase 3)Active Not RecruitingNCT06670196
What this trial is testing

SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 420
Early research (Phase 1)Study completedNCT06525246
What this trial is testing

Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

Who this might be right for
Stage IIIB Non-small Cell Lung CancerStage IIIC Non-Small Cell Lung CancerStage IV Non-small Cell Lung Cancer+2 more
Ono Pharmaceutical Co., Ltd. 78
Not applicableStudy completedNCT01255150
What this trial is testing

Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Carcinoma
National Cancer Institute (NCI) 15
Large-scale testing (Phase 3)Study completedNCT00874419
What this trial is testing

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

Who this might be right for
Non-small Cell Lung Cancer
Tongji University 165
Testing effectiveness (Phase 2)Active Not RecruitingNCT05801029
What this trial is testing

Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Large-scale testing (Phase 3)UnknownNCT02886195
What this trial is testing

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

Who this might be right for
EGFR Gene Mutation
Fujian Cancer Hospital 120
Large-scale testing (Phase 3)Looking for participantsNCT06452277
What this trial is testing

Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Who this might be right for
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer 555
Testing effectiveness (Phase 2)Looking for participantsNCT06760819
What this trial is testing

Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Who this might be right for
Advanced Solid TumorsHER2 Mutation
Bayer 111
Not applicableStudy completedNCT04206787
What this trial is testing

The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-squamous, Non-Small Cell Lung Cancer
Boehringer Ingelheim 72
Testing effectiveness (Phase 2)UnknownNCT04811001
What this trial is testing

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

Who this might be right for
NSCLC
Fondazione Ricerca Traslazionale 170
Not applicableUnknownNCT01717105
What this trial is testing

Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients

Who this might be right for
Metastatic Non-Small-Cell Lung Cancer
Grupo Gallego de Cancer de Pulmon 225
Early research (Phase 1)Ended earlyNCT03065387
What this trial is testing

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Who this might be right for
Advanced Malignant Solid NeoplasmEGFR Gene AmplificationEGFR Gene Mutation+7 more
M.D. Anderson Cancer Center 84
Not applicableUnknownNCT00903292
What this trial is testing

Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Non-Small Cell Lung Cancer
National Cheng-Kung University Hospital 52
Large-scale testing (Phase 3)UnknownNCT03008109
What this trial is testing

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Who this might be right for
Advanced CancerLung Cancer, Nonsmall Cell
Zaiwen Fan 80
Large-scale testing (Phase 3)Study completedNCT02151981
What this trial is testing

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Anticancer Treatment
AstraZeneca 421
Not applicableLooking for participantsNCT05598528
What this trial is testing

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

Who this might be right for
Lung Cancer, Non-small CellEGFR Gene MutationEGFR-TKI Resistant Mutation+2 more
Second Xiangya Hospital of Central South University 210
Large-scale testing (Phase 3)Temporarily pausedNCT05378763
What this trial is testing

Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

Who this might be right for
NSCLC
Spectrum Pharmaceuticals, Inc 268
Testing effectiveness (Phase 2)Study completedNCT01573702
What this trial is testing

Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

Who this might be right for
Non Small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center 32
Next Page